| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
Penicillin-binding proteins (PBPs). Penicillin G procaine is a β-lactam antibiotic that binds to penicillin-binding proteins (PBPs). PBPs are enzymes that catalyze the synthesis of peptidoglycan, a critical component of the bacterial cell wall. By binding to PBPs, Penicillin G procaine inhibits transpeptidase activity, disrupting cell wall biosynthesis and leading to bacterial cell lysis and death. The compound is a natural penicillin. It displays antibacterial efficacy against gram-positive bacteria.
|
|---|---|
| ln Vitro |
Penicillin G procaine demonstrates antibacterial activity in vitro against a range of gram-positive bacteria. Its activity is assessed by standard antimicrobial susceptibility testing methods (broth microdilution or agar diffusion). The compound's minimum inhibitory concentrations (MICs) against susceptible strains are well-characterized. Penicillin G procaine is a β-lactam antibiotic.
|
| ln Vivo |
Penicillin G procaine is used for the treatment of moderately severe infections caused by organisms susceptible to the low, prolonged serum concentrations of penicillin G provided by IM administration. The compound is administered intramuscularly. Its in vivo efficacy has been established through clinical use since 1948. Penicillin G procaine displays poor oral absorption kinetics and must be administered by injection. The compound is indicated for infection.
|
| Enzyme Assay |
Antibacterial susceptibility testing is performed using broth microdilution or agar dilution methods according to CLSI guidelines. Bacterial strains (e.g., S. aureus, S. pneumoniae) are cultured in appropriate media. Penicillin G procaine is serially diluted and tested against the bacteria. MIC values are determined as the lowest concentration causing complete inhibition of visible growth. Quality control strains are included to ensure assay validity.
|
| Cell Assay |
Antibacterial activity is evaluated in bacterial cell cultures using standard microbiological methods. Broth microdilution assays are performed in 96-well plates with appropriate media. Bacteria are cultured to logarithmic phase and diluted to a standard inoculum. Penicillin G procaine is serially diluted and added to wells. Plates are incubated at 35°C for 16-20 hours. MIC values are determined visually or using a microplate reader. Each experiment includes quality control strains and antibiotic standards.
|
| Animal Protocol |
In vivo efficacy is evaluated in animal models of bacterial infection. Penicillin G procaine is administered intramuscularly at doses determined by preclinical studies. Bacterial burden is quantified in infected tissues by CFU plating. Clinical symptoms are monitored. Sample sizes typically range from 6-10 animals per group. Clinical studies have been conducted for various infections.
|
| ADME/Pharmacokinetics |
Molecular Weight: 588.7. CAS No.: 6130-64-9. Potency: 900-1050 Penicillin G Units/mg. Appearance: Solid. Solubility: Water. Storage: Typically at 2-8°C. Penicillin G procaine is a β-lactam antibiotic used for moderately severe infections.
|
| Toxicity/Toxicokinetics |
Penicillin G procaine is generally well-tolerated at therapeutic doses. Common adverse effects may include allergic reactions (rash, anaphylaxis), gastrointestinal disturbances, and injection site reactions. As a penicillin, it is contraindicated in patients with penicillin hypersensitivity. Standard toxicology studies have demonstrated an acceptable safety profile for its approved uses. Penicillin G procaine was first approved in 1948.
|
| References |
Farrar GE Jr. Penicillin G, penicillin V, and other pharmaceutical improvements in the treatment of infections. Clin Ther. 1990 Jan-Feb;12(1):78-9. PubMed PMID: 2109661.
|
| Additional Infomation |
Penicillin G is the procaine form of penicillin G, a broad-spectrum β-lactam antibiotic with natural penicillin activity. Penicillin G binds to and inactivates penicillin-binding proteins (PBPs) located within the bacterial cell wall. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains, which is crucial for the strength and rigidity of the bacterial cell wall. This disrupts bacterial cell wall synthesis, leading to cell wall weakening and ultimately cell lysis. Semi-synthetic antibiotics are prepared by conjugating penicillin G with procaine. See also: Penicillin G (note moved to).
Penicillin G procaine is also known as Crysticillin, Duracillin, and Bactracillin G. Its CAS name is (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid compound with 2-(diethylamino)ethyl 4-aminobenzoate (1:1) monohydrate. Penicillin G procaine is a natural penicillin and β-lactam antibiotic. It is used for moderately severe infections caused by susceptible organisms. It is administered intramuscularly. It was first approved in 1948. Regulatory approvals exist in many countries. |
| Molecular Formula |
C29H40N4O7S
|
|---|---|
| Molecular Weight |
588.72
|
| Exact Mass |
589.27
|
| Elemental Analysis |
C, 59.17; H, 6.85; N, 9.52; O, 19.02; S, 5.45
|
| CAS # |
6130-64-9
|
| Related CAS # |
Penicillin G potassium;113-98-4;Penicillin G sodium salt;69-57-8;Penicillin G benzathine;1538-09-6;Penicillin G benzathine tetrahydrate;41372-02-5;Procaine benzylpenicillin;54-35-3;Penicillin G;61-33-6
|
| PubChem CID |
22502
|
| Appearance |
Solid powder
|
| Density |
1.255-1.256 g/cm3 (20ºC)
|
| Boiling Point |
663.3ºC at 760 mmHg
|
| Melting Point |
106-110ºC
|
| Flash Point |
355ºC
|
| LogP |
3.372
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
41
|
| Complexity |
752
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
O.CCN(CCOC(C1C=CC(N)=CC=1)=O)CC.O=C(N[C@@H]1C(=O)N2[C@H](C(S[C@H]12)(C)C)C(=O)O)CC1C=CC=CC=1
|
| InChi Key |
KZDCMKVLEYCGQX-UDPGNSCCSA-N
|
| InChi Code |
1S/C16H18N2O4S.C13H20N2O2.H2O/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-91-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)5-8H,3-4,9-10,14H2,1-2H31H2/t11-,12+,14-/m1../s1
|
| Chemical Name |
Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester, mono((2S,5R,6R)-3,3-dimethyl-7-oxo-6-((phenylacetyl)amino)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate), monohydrate
|
| Synonyms |
Abbocillin;Abbocillin DC;Afsillin;Ampin-penicillin;Aquacillin;Aquasuspen;Avloprocil;Bactracillin G;Benzylpenicillin procaine monohydrate;Cilicaine;Crysticillin;Depo-Penicillin;Distaquaine;Diurnal-Penicillin;Duracillin;Duracillin A.S.;Flo-Cillin;Penicillin G procaine;Penicillin 100;Procaine penicillin G hydrate;Procaine penicillin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
） : 250 mg/mL (424.65 mM
H2O:~ 3.14 mg/mL (~5.33 mM） |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.53 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.53 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.53 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 6.67 mg/mL (11.33 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6986 mL | 8.4930 mL | 16.9860 mL | |
| 5 mM | 0.3397 mL | 1.6986 mL | 3.3972 mL | |
| 10 mM | 0.1699 mL | 0.8493 mL | 1.6986 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
